Deciphering hypertrophic cardiomyopathy with electrocardiography.
Arrhythmia
Cardiac hypertrophy
Electrocardiography
Hypertrophic cardiomyopathy
Myocardial fibrosis
Sudden cardiac death
Journal
Heart failure reviews
ISSN: 1573-7322
Titre abrégé: Heart Fail Rev
Pays: United States
ID NLM: 9612481
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
accepted:
10
07
2021
pubmed:
22
7
2021
medline:
18
6
2022
entrez:
21
7
2021
Statut:
ppublish
Résumé
The comprehensive assessment of patients with hypertrophic cardiomyopathy is a complex process, with each step concurrently focusing on confirmation of the diagnosis, differentiation between sarcomeric and non-sarcomeric disease (phenocopy), and prognostication. Novel modalities such as genetic testing and advanced imaging have allowed for substantial advancements in the understanding of this condition and facilitate patient management. However, their availability is at present not universal, and interpretation requires a high level of expertise. In this setting, electrocardiography, a fast and widely available method, still retains a significant role in everyday clinical assessment of this population. In our review, we follow a stepwise approach for the interpretation of each electrocardiographic segment, discussing clinical implications of electrocardiographic patterns in sarcomeric disease, their value in the differential diagnosis from phenocopies, and impact on patient management. Outlining the substantial amount of information to be obtained from a simple tracing, we exhibit how electrocardiography is likely to remain an integral diagnostic tool in the future as well.
Identifiants
pubmed: 34286451
doi: 10.1007/s10741-021-10147-0
pii: 10.1007/s10741-021-10147-0
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1313-1323Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW (2011) 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 124:2761–2796. https://doi.org/10.1161/CIR.0b013e318223e230
doi: 10.1161/CIR.0b013e318223e230
pubmed: 22068435
Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege AA, Lafont A, Limongelli G, Mahrholdt H, McKenna WJ, Mogensen J, Nihoyannopoulos P, Nistri S, Pieper PG, Pieske B, Rapezzi C, Rutten FH, Tillmanns C, Watkins H (2014) 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 35:2733–2779. https://doi.org/10.1093/eurheartj/ehu284
doi: 10.1093/eurheartj/ehu284
pubmed: 25173338
McLeod CJ, Ackerman MJ, Nishimura RA, Tajik AJ, Gersh BJ, Ommen SR (2009) Outcome of patients with hypertrophic cardiomyopathy and a normal electrocardiogram. J Am Coll Cardiol 54:229–233. https://doi.org/10.1016/j.jacc.2009.02.071
doi: 10.1016/j.jacc.2009.02.071
pubmed: 19589435
Siontis KC, Geske JB, Ong K, Nishimura RA, Ommen SR, Gersh BJ (2014) Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical correlations, and mortality in a large high-risk population. J Am Heart Assoc 3:e001002. https://doi.org/10.1161/jaha.114.001002
doi: 10.1161/jaha.114.001002
pubmed: 24965028
pmcid: 4309084
Guttmann OP, Rahman MS, O’Mahony C, Anastasakis A, Elliott PM (2014) Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review. Heart 100:465–472. https://doi.org/10.1136/heartjnl-2013-304276
doi: 10.1136/heartjnl-2013-304276
pubmed: 24014282
Vaidya K, Semsarian C, Chan KH (2017) Atrial fibrillation in hypertrophic cardiomyopathy. Heart Lung Circ 26:975–982. https://doi.org/10.1016/j.hlc.2017.05.116
doi: 10.1016/j.hlc.2017.05.116
pubmed: 28602671
Rowin EJ, Hausvater A, Link MS, Abt P, Gionfriddo W, Wang W, Rastegar H, Estes NAM, Maron MS, Maron BJ (2017) Clinical profile and consequences of atrial fibrillation in hypertrophic cardiomyopathy. Circulation 136:2420–2436. https://doi.org/10.1161/circulationaha.117.029267
doi: 10.1161/circulationaha.117.029267
pubmed: 28916640
Papavassiliu T, Germans T, Flüchter S, Doesch C, Suriyakamar A, Haghi D, Süselbeck T, Wolpert C, Dinter D, Schoenberg SO, van Rossum AC, Borggrefe M (2009) CMR findings in patients with hypertrophic cardiomyopathy and atrial fibrillation. J Cardiovasc Magn Reson 11:34. https://doi.org/10.1186/1532-429x-11-34
doi: 10.1186/1532-429x-11-34
pubmed: 19740409
pmcid: 2749835
Sivalokanathan S, Zghaib T, Greenland GV, Vasquez N, Kudchadkar SM, Kontari E, Lu DY, Dolores-Cerna K, van der Geest RJ, Kamel IR, Olgin JE, Abraham TP, Nazarian S, Zimmerman SL, Abraham MR (2019) Hypertrophic cardiomyopathy patients with paroxysmal atrial fibrillation have a high burden of left atrial fibrosis by cardiac magnetic resonance imaging. JACC Clin Electrophysiol 5:364–375. https://doi.org/10.1016/j.jacep.2018.10.016
doi: 10.1016/j.jacep.2018.10.016
pubmed: 30898240
Lee SE, Park JK, Uhm JS, Kim JY, Pak HN, Lee MH, Joung B (2017) Impact of atrial fibrillation on the clinical course of apical hypertrophic cardiomyopathy. Heart 103:1496–1501. https://doi.org/10.1136/heartjnl-2016-310720
doi: 10.1136/heartjnl-2016-310720
pubmed: 28428444
Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ (2001) Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 104:2517–2524. https://doi.org/10.1161/hc4601.097997
doi: 10.1161/hc4601.097997
pubmed: 11714644
Zegkos T, Efthimiadis GK, Parcharidou DG, Gossios TD, Giannakoulas G, Ntelios D, Ziakas A, Paraskevaidis S, Karvounis HI (2017) Atrial fibrillation in hypertrophic cardiomyopathy: a turning point towards increased morbidity and mortality. Hellenic J Cardiol 58:331–339. https://doi.org/10.1016/j.hjc.2017.01.027
doi: 10.1016/j.hjc.2017.01.027
pubmed: 28219794
Monserrat L, Elliott PM, Gimeno JR, Sharma S, Penas-Lado M, McKenna WJ (2003) Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol 42:873–879. https://doi.org/10.1016/s0735-1097(03)00827-1
doi: 10.1016/s0735-1097(03)00827-1
pubmed: 12957435
Gimeno JR, Tomé-Esteban M, Lofiego C, Hurtado J, Pantazis A, Mist B, Lambiase P, McKenna WJ, Elliott PM (2009) Exercise-induced ventricular arrhythmias and risk of sudden cardiac death in patients with hypertrophic cardiomyopathy. Eur Heart J 30:2599–2605. https://doi.org/10.1093/eurheartj/ehp327
doi: 10.1093/eurheartj/ehp327
pubmed: 19689975
Sedaghat-Hamedani F, Kayvanpour E, Tugrul OF, Lai A, Amr A, Haas J, Proctor T, Ehlermann P, Jensen K, Katus HA, Meder B (2018) Clinical outcomes associated with sarcomere mutations in hypertrophic cardiomyopathy: a meta-analysis on 7675 individuals. Clin Res Cardiol 107:30–41. https://doi.org/10.1007/s00392-017-1155-5
doi: 10.1007/s00392-017-1155-5
pubmed: 28840316
Liebregts M, Vriesendorp PA, Mahmoodi BK, Schinkel AF, Michels M, ten Berg JM (2015) A systematic review and meta-analysis of long-term outcomes after septal reduction therapy in patients with hypertrophic cardiomyopathy. JACC Heart Fail 3:896–905. https://doi.org/10.1016/j.jchf.2015.06.011
doi: 10.1016/j.jchf.2015.06.011
pubmed: 26454847
Giancaterino S, Urey MA, Darden D, Hsu JC (2020) Management of arrhythmias in cardiac amyloidosis. JACC Clin Electrophysiol 6:351–361. https://doi.org/10.1016/j.jacep.2020.01.004
doi: 10.1016/j.jacep.2020.01.004
pubmed: 32327068
O’Mahony C, Coats C, Cardona M, Garcia A, Calcagnino M, Murphy E, Lachmann R, Mehta A, Hughes D, Elliott PM (2011) Incidence and predictors of anti-bradycardia pacing in patients with Anderson-Fabry disease. Europace 13:1781–1788. https://doi.org/10.1093/europace/eur267
doi: 10.1093/europace/eur267
pubmed: 21856674
Gollob MH, Green MS, Tang AS, Roberts R (2002) PRKAG2 cardiac syndrome: familial ventricular preexcitation, conduction system disease, and cardiac hypertrophy. Curr Opin Cardiol 17:229–234. https://doi.org/10.1097/00001573-200205000-00004
doi: 10.1097/00001573-200205000-00004
pubmed: 12015471
Eriksson P, Karp K, Bjerle P, Olofsson BO (1984) Disturbances of cardiac rhythm and conduction in familial amyloidosis with polyneuropathy. Br Heart J 51:658–662. https://doi.org/10.1136/hrt.51.6.658
doi: 10.1136/hrt.51.6.658
pubmed: 6329251
pmcid: 481569
Efthimiadis GK, Giannakoulas G, Parcharidou DG, Pagourelias ED, Kouidi EJ, Spanos G, Kamperidis V, Gavrielides S, Karvounis H, Styliadis I, Parcharidis GE (2011) Chronotropic incompetence and its relation to exercise intolerance in hypertrophic cardiomyopathy. Int J Cardiol 153:179–184. https://doi.org/10.1016/j.ijcard.2010.08.026
doi: 10.1016/j.ijcard.2010.08.026
pubmed: 20851477
Luo HC, Dimaano VL, Kembro JM, Hilser A, Hurtado-de-Mendoza D, Pozios I, Tomas MS, Yalcin H, Dolores-Cerna K, Mormontoy W, Aon MA, Cameron D, Bluemke DA, Stewart KJ, Russell SD, Cordova JG, Abraham TP, Abraham MR (2015) Exercise heart rates in patients with hypertrophic cardiomyopathy. Am J Cardiol 115:1144–1150. https://doi.org/10.1016/j.amjcard.2015.01.548
doi: 10.1016/j.amjcard.2015.01.548
pubmed: 25746289
pmcid: 5811205
Holmqvist F, Platonov PG, Carlson J, Havmöller R, Waktare JE, McKenna WJ, Olsson SB, Meurling CJ (2007) Variable interatrial conduction illustrated in a hypertrophic cardiomyopathy population. Ann Noninvasive Electrocardiol 12:227–236. https://doi.org/10.1111/j.1542-474X.2007.00166.x
doi: 10.1111/j.1542-474X.2007.00166.x
pubmed: 17617068
pmcid: 6932290
Girasis C, Vassilikos V, Efthimiadis GK, Papadopoulou SL, Dakos G, Dalamaga EG, Chouvarda I, Giannakoulas G, Kamperidis V, Paraskevaidis S, Maglaveras N, Karvounis HI, Parcharidis GE, Styliadis IH (2013) Patients with hypertrophic cardiomyopathy at risk for paroxysmal atrial fibrillation: advanced echocardiographic evaluation of the left atrium combined with non-invasive P-wave analysis. Eur Heart J Cardiovasc Imaging 14:425–434. https://doi.org/10.1093/ehjci/jes172
doi: 10.1093/ehjci/jes172
pubmed: 22902322
Cecchi F, Montereggi A, Olivotto I, Marconi P, Dolara A, Maron BJ (1997) Risk for atrial fibrillation in patients with hypertrophic cardiomyopathy assessed by signal averaged P wave duration. Heart 78:44–49. https://doi.org/10.1136/hrt.78.1.44
doi: 10.1136/hrt.78.1.44
pubmed: 9290401
pmcid: 484863
Köse S, Aytemir K, Sade E, Can I, Ozer N, Amasyali B, Aksöyek S, Ovünç K, Ozmen F, Atalar E, Işik E, Kes S, Demirtaş E, Oto A (2003) Detection of patients with hypertrophic cardiomyopathy at risk for paroxysmal atrial fibrillation during sinus rhythm by P-wave dispersion. Clin Cardiol 26:431–434. https://doi.org/10.1002/clc.4960260910
doi: 10.1002/clc.4960260910
pubmed: 14524601
Ozdemir O, Soylu M, Demir AD, Topaloglu S, Alyan O, Turhan H, Bicer A, Kutuk E (2004) P-wave durations as a predictor for atrial fibrillation development in patients with hypertrophic cardiomyopathy. Int J Cardiol 94:163–166. https://doi.org/10.1016/j.ijcard.2003.01.001
doi: 10.1016/j.ijcard.2003.01.001
pubmed: 15093974
Tuluce K, Ozerkan F, Yakar Tuluce S, Yavuzgil O, Gurgun C, Bilgin M, Kahya Eren N, Kocabas U, Nalbantgil S, Soydas Cinar C (2015) Relationships between P wave dispersion, atrial electromechanical delay, left atrial remodeling, and NT-proBNP levels, in patients with hypertrophic cardiomyopathy. Cardiol J 22:94–100. https://doi.org/10.5603/CJ.a2014.0025
doi: 10.5603/CJ.a2014.0025
pubmed: 24671901
Higuchi S, Minami Y, Shoda M, Shirotani S, Saito C, Haruki S, Gotou M, Yagishita D, Ejima K, Hagiwara N (2020) Prognostic implication of first-degree atrioventricular block in patients with hypertrophic cardiomyopathy. J Am Heart Assoc 9:e015064. https://doi.org/10.1161/jaha.119.015064
doi: 10.1161/jaha.119.015064
pubmed: 32146896
pmcid: 7335505
Patel SI, Ackerman MJ, Shamoun FE, Geske JB, Ommen SR, Love WT, Cha SS, Bos JM, Lester SJ (2019) QT prolongation and sudden cardiac death risk in hypertrophic cardiomyopathy. Acta Cardiol 74:53–58. https://doi.org/10.1080/00015385.2018.1440905
doi: 10.1080/00015385.2018.1440905
pubmed: 29513133
Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, Salvi F, Ciliberti P, Pastorelli F, Biagini E, Coccolo F, Cooke RM, Bacchi-Reggiani L, Sangiorgi D, Ferlini A, Cavo M, Zamagni E, Fonte ML, Palladini G, Salinaro F, Musca F, Obici L, Branzi A, Perlini S (2009) Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 120:1203–1212. https://doi.org/10.1161/circulationaha.108.843334
doi: 10.1161/circulationaha.108.843334
pubmed: 19752327
Ikari Y, Kuwako K, Yamaguchi T (1992) Fabry’s disease with complete atrioventricular block: histological evidence of involvement of the conduction system. Br Heart J 68:323–325. https://doi.org/10.1136/hrt.68.9.323
doi: 10.1136/hrt.68.9.323
pubmed: 1389767
pmcid: 1025080
DiMauro S, Schon EA (2003) Mitochondrial respiratory-chain diseases. N Engl J Med 348:2656–2668. https://doi.org/10.1056/NEJMra022567
doi: 10.1056/NEJMra022567
pubmed: 12826641
Sharma S, Drezner JA, Baggish A, Papadakis M, Wilson MG, Prutkin JM, La Gerche A, Ackerman MJ, Borjesson M, Salerno JC, Asif IM, Owens DS, Chung EH, Emery MS, Froelicher VF, Heidbuchel H, Adamuz C, Asplund CA, Cohen G, Harmon KG, Marek JC, Molossi S, Niebauer J, Pelto HF, Perez MV, Riding NR, Saarel T, Schmied CM, Shipon DM, Stein R, Vetter VL, Pelliccia A, Corrado D (2017) International recommendations for electrocardiographic interpretation in athletes. J Am Coll Cardiol 69:1057–1075. https://doi.org/10.1016/j.jacc.2017.01.015
doi: 10.1016/j.jacc.2017.01.015
pubmed: 28231933
Gollob MH, Green MS, Tang AS, Gollob T, Karibe A, Ali Hassan AS, Ahmad F, Lozado R, Shah G, Fananapazir L, Bachinski LL, Roberts R (2001) Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N Engl J Med 344:1823–1831. https://doi.org/10.1056/nejm200106143442403
doi: 10.1056/nejm200106143442403
pubmed: 11407343
Boucek D, Jirikowic J, Taylor M (2011) Natural history of Danon disease. Genet Med 13:563–568. https://doi.org/10.1097/GIM.0b013e31820ad795
doi: 10.1097/GIM.0b013e31820ad795
pubmed: 21415759
Bharati S, Serratto M, DuBrow I, Paul MH, Swiryn S, Miller RA, Rosen K, Lev M (1982) The conduction system in Pompe’s disease. Pediatr Cardiol 2:25–32. https://doi.org/10.1007/bf02265613
doi: 10.1007/bf02265613
pubmed: 6460990
López-Sainz Á, Salazar-Mendiguchía J, García-Álvarez A, Campuzano Larrea O, López-Garrido M, García-Guereta L, Fuentes Cañamero ME, Climent Payá V, Peña-Peña ML, Zorio-Grima E, Jordá-Burgos P, Díez-López C, Brugada R, García-Pinilla JM, García-Pavía P (2019) Clinical findings and prognosis of Danon disease. An Analysis of the Spanish Multicenter Danon Registry. Rev Esp Cardiol (Engl Ed) 72:479–486. https://doi.org/10.1016/j.rec.2018.04.035
doi: 10.1016/j.rec.2018.04.035
Konrad T, Sonnenschein S, Schmidt FP, Mollnau H, Bock K, Ocete BQ, Münzel T, Theis C, Rostock T (2017) Cardiac arrhythmias in patients with Danon disease. Europace 19:1204–1210. https://doi.org/10.1093/europace/euw215
doi: 10.1093/europace/euw215
pubmed: 27742774
Namdar M, Steffel J, Vidovic M, Brunckhorst CB, Holzmeister J, Lüscher TF, Jenni R, Duru F (2011) Electrocardiographic changes in early recognition of Fabry disease. Heart 97:485–490. https://doi.org/10.1136/hrt.2010.211789
doi: 10.1136/hrt.2010.211789
pubmed: 21270075
Levine JC, Kishnani PS, Chen YT, Herlong JR, Li JS (2008) Cardiac remodeling after enzyme replacement therapy with acid alpha-glucosidase for infants with Pompe disease. Pediatr Cardiol 29:1033–1042. https://doi.org/10.1007/s00246-008-9267-3
doi: 10.1007/s00246-008-9267-3
pubmed: 18661169
pmcid: 2683920
Prinz C, Farr M, Hering D, Horstkotte D, Faber L (2010) Reduction in ECG abnormalities and improvement of regional left ventricular function in a patient with Fabry’s disease during enzyme-replacement therapy. Clin Res Cardiol 99:53–55. https://doi.org/10.1007/s00392-009-0084-3
doi: 10.1007/s00392-009-0084-3
pubmed: 19774328
Topilski I, Sherez J, Keren G, Copperman I (2006) Long-term effects of dual-chamber pacing with periodic echocardiographic evaluation of optimal atrioventricular delay in patients with hypertrophic cardiomyopathy >50 years of age. Am J Cardiol 97:1769–1775. https://doi.org/10.1016/j.amjcard.2006.01.040
doi: 10.1016/j.amjcard.2006.01.040
pubmed: 16765132
Montgomery JV, Harris KM, Casey SA, Zenovich AG, Maron BJ (2005) Relation of electrocardiographic patterns to phenotypic expression and clinical outcome in hypertrophic cardiomyopathy. Am J Cardiol 96:270–275. https://doi.org/10.1016/j.amjcard.2005.03.058
doi: 10.1016/j.amjcard.2005.03.058
pubmed: 16018856
Calore C, Zorzi A, Corrado D (2015) Clinical meaning of isolated increase of QRS voltages in hypertrophic cardiomyopathy versus athlete’s heart. J Electrocardiol 48:373–379. https://doi.org/10.1016/j.jelectrocard.2014.12.016
doi: 10.1016/j.jelectrocard.2014.12.016
pubmed: 25595718
Calore C, Melacini P, Pelliccia A, Cianfrocca C, Schiavon M, Di Paolo FM, Bovolato F, Quattrini FM, Basso C, Thiene G, Iliceto S, Corrado D (2013) Prevalence and clinical meaning of isolated increase of QRS voltages in hypertrophic cardiomyopathy versus athlete’s heart: relevance to athletic screening. Int J Cardiol 168:4494–4497. https://doi.org/10.1016/j.ijcard.2013.06.123
doi: 10.1016/j.ijcard.2013.06.123
pubmed: 23928341
Guerrier K, Anderson JB, Pratt J, King EC, Statile C, Wilmot I, Campbell M, Czosek RJ (2015) Correlation of precordial voltages to left ventricular mass on echocardiogram in adolescent patients with hypertrophic cardiomyopathy compared with that in adolescent athletes. Am J Cardiol 115:956–961. https://doi.org/10.1016/j.amjcard.2015.01.025
doi: 10.1016/j.amjcard.2015.01.025
pubmed: 25670640
Maron BJ, Wolfson JK, Ciró E, Spirito P (1983) Relation of electrocardiographic abnormalities and patterns of left ventricular hypertrophy identified by 2-dimensional echocardiography in patients with hypertrophic cardiomyopathy. Am J Cardiol 51:189–194. https://doi.org/10.1016/s0002-9149(83)80034-4
doi: 10.1016/s0002-9149(83)80034-4
pubmed: 6217739
Chatterjee D, Narayan P (2018) Idiopathic isolated right ventricular apical hypertrophy. Acta Cardiol Sin 34:288–290. https://doi.org/10.6515/acs.201805_34(3).20180122a
doi: 10.6515/acs.201805_34(3).20180122a
pubmed: 29844651
pmcid: 5968346
Pagourelias ED, Efthimiadis GK, Parcharidou DG, Gossios TD, Kamperidis V, Karoulas T, Karvounis H, Styliadis IH (2011) Prognostic value of right ventricular diastolic function indices in hypertrophic cardiomyopathy. Eur J Echocardiogr 12:809–817. https://doi.org/10.1093/ejechocard/jer126
doi: 10.1093/ejechocard/jer126
pubmed: 21846651
Maron BJ, Roberts WC, Arad M, Haas TS, Spirito P, Wright GB, Almquist AK, Baffa JM, Saul JP, Ho CY, Seidman J, Seidman CE (2009) Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy. JAMA 301:1253–1259. https://doi.org/10.1001/jama.2009.371
doi: 10.1001/jama.2009.371
pubmed: 19318653
pmcid: 4106257
Arad M, Maron BJ, Gorham JM, Johnson WH Jr, Saul JP, Perez-Atayde AR, Spirito P, Wright GB, Kanter RJ, Seidman CE, Seidman JG (2005) Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med 352:362–372. https://doi.org/10.1056/NEJMoa033349
doi: 10.1056/NEJMoa033349
pubmed: 15673802
Cyrille NB, Goldsmith J, Alvarez J, Maurer MS (2014) Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis. Am J Cardiol 114:1089–1093. https://doi.org/10.1016/j.amjcard.2014.07.026
doi: 10.1016/j.amjcard.2014.07.026
pubmed: 25212550
Konno T, Nagata Y, Teramoto R, Fujino N, Nomura A, Tada H, Sakata K, Furusho H, Takamura M, Nakamura H, Kawashiri MA, Yamagishi M, Hayashi K (2016) Usefulness of electrocardiographic voltage to determine myocardial fibrosis in hypertrophic cardiomyopathy. Am J Cardiol 117:443–449. https://doi.org/10.1016/j.amjcard.2015.11.015
doi: 10.1016/j.amjcard.2015.11.015
pubmed: 26705881
Biagini E, Pazzi C, Olivotto I, Musumeci B, Limongelli G, Boriani G, Pacileo G, Mastromarino V, Bacchi Reggiani ML, Lorenzini M, Lai F, Berardini A, Mingardi F, Rosmini S, Resciniti E, Borghi C, Autore C, Cecchi F, Rapezzi C (2016) Usefulness of electrocardiographic patterns at presentation to predict long-term risk of cardiac death in patients with hypertrophic cardiomyopathy. Am J Cardiol 118:432–439. https://doi.org/10.1016/j.amjcard.2016.05.023
doi: 10.1016/j.amjcard.2016.05.023
pubmed: 27289293
Koga Y, Yamaga A, Hiyamuta K, Ikeda H, Toshima H (2004) Mechanisms of abnormal Q waves in hypertrophic cardiomyopathy assessed by intracoronary electrocardiography. J Cardiovasc Electrophysiol 15:1402–1408. https://doi.org/10.1046/j.1540-8167.2004.04314.x
doi: 10.1046/j.1540-8167.2004.04314.x
pubmed: 15610287
Maron BJ, Epstein SE, Roberts WC (1979) Hypertrophic cardiomyopathy and transmural myocardial infarction without significant atherosclerosis of the extramural coronary arteries. Am J Cardiol 43:1086–1102. https://doi.org/10.1016/0002-9149(79)90139-5
doi: 10.1016/0002-9149(79)90139-5
pubmed: 571670
Fronza M, Raineri C, Valentini A, Bassi EM, Scelsi L, Buscemi ML, Turco A, Castelli G, Ghio S, Visconti LO (2016) Relationship between electrocardiographic findings and Cardiac Magnetic Resonance phenotypes in patients with Hypertrophic Cardiomyopathy. Int J Cardiol Heart Vasc 11:7–11. https://doi.org/10.1016/j.ijcha.2016.02.001
doi: 10.1016/j.ijcha.2016.02.001
pubmed: 28616518
pmcid: 5462632
Dumont CA, Monserrat L, Soler R, Rodríguez E, Fernandez X, Peteiro J, Bouzas A, Bouzas B, Castro-Beiras A (2006) Interpretation of electrocardiographic abnormalities in hypertrophic cardiomyopathy with cardiac magnetic resonance. Eur Heart J 27:1725–1731. https://doi.org/10.1093/eurheartj/ehl101
doi: 10.1093/eurheartj/ehl101
pubmed: 16774982
Lemery R, Kleinebenne A, Nihoyannopoulos P, Aber V, Alfonso F, McKenna WJ (1990) Q waves in hypertrophic cardiomyopathy in relation to the distribution and severity of right and left ventricular hypertrophy. J Am Coll Cardiol 16:368–374. https://doi.org/10.1016/0735-1097(90)90587-f
doi: 10.1016/0735-1097(90)90587-f
pubmed: 2373813
Ohmoto-Sekine Y, Suzuki J, Shimamoto R, Yamazaki T, Tsuji T, Nagai R, Ohtomo K (2007) Gender-specific clinical characteristics of deep Q waves in hypertrophic cardiomyopathy. Gend Med 4:274–283. https://doi.org/10.1016/s1550-8579(07)80046-5
doi: 10.1016/s1550-8579(07)80046-5
pubmed: 18022593
Konno T, Shimizu M, Ino H, Yamaguchi M, Terai H, Uchiyama K, Oe K, Mabuchi T, Kaneda T, Mabuchi H (2004) Diagnostic value of abnormal Q waves for identification of preclinical carriers of hypertrophic cardiomyopathy based on a molecular genetic diagnosis. Eur Heart J 25:246–251. https://doi.org/10.1016/j.ehj.2003.10.031
doi: 10.1016/j.ehj.2003.10.031
pubmed: 14972426
Savage DD, Seides SF, Clark CE, Henry WL, Maron BJ, Robinson FC, Epstein SE (1978) Electrocardiographic findings in patients with obstructive and nonobstructive hypertrophic cardiomyopathy. Circulation 58:402–408. https://doi.org/10.1161/01.cir.58.3.402
doi: 10.1161/01.cir.58.3.402
pubmed: 567104
Nasermoaddeli A, Miura K, Matsumori A, Soyama Y, Morikawa Y, Kitabatake A, Inaba Y, Nakagawa H (2007) Prognosis and prognostic factors in patients with hypertrophic cardiomyopathy in Japan: results from a nationwide study. Heart 93:711–715. https://doi.org/10.1136/hrt.2006.095232
doi: 10.1136/hrt.2006.095232
pubmed: 17085533
Killu AM, Park JY, Sara JD, Hodge DO, Gersh BJ, Nishimura RA, Asirvatham SJ, McLeod CJ (2018) Cardiac resynchronization therapy in patients with end-stage hypertrophic cardiomyopathy. Europace 20:82–88. https://doi.org/10.1093/europace/euw327
doi: 10.1093/europace/euw327
pubmed: 29315424
Rogers DP, Marazia S, Chow AW, Lambiase PD, Lowe MD, Frenneaux M, McKenna WJ, Elliott PM (2008) Effect of biventricular pacing on symptoms and cardiac remodelling in patients with end-stage hypertrophic cardiomyopathy. Eur J Heart Fail 10:507–513. https://doi.org/10.1016/j.ejheart.2008.03.006
doi: 10.1016/j.ejheart.2008.03.006
pubmed: 18406204
Patel V, O’Mahony C, Hughes D, Rahman MS, Coats C, Murphy E, Lachmann R, Mehta A, Elliott PM (2015) Clinical and genetic predictors of major cardiac events in patients with Anderson-Fabry disease. Heart 101:961–966. https://doi.org/10.1136/heartjnl-2014-306782
doi: 10.1136/heartjnl-2014-306782
pubmed: 25655062
Raaijmakers R, Noordam C, Noonan JA, Croonen EA, van der Burgt CJ, Draaisma JM (2008) Are ECG abnormalities in Noonan syndrome characteristic for the syndrome? Eur J Pediatr 167:1363–1367. https://doi.org/10.1007/s00431-008-0670-9
doi: 10.1007/s00431-008-0670-9
pubmed: 18270737
Debonnaire P, Katsanos S, Joyce E, OV VDB, Atsma DE, Schalij MJ, Bax JJ, Delgado V, Marsan NA, (2015) QRS fragmentation and QTc duration relate to malignant ventricular tachyarrhythmias and sudden cardiac death in patients with hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol 26:547–555. https://doi.org/10.1111/jce.12629
doi: 10.1111/jce.12629
pubmed: 25648421
Femenía F, Arce M, Van Grieken J, Trucco E, Mont L, Abello M, Merino JL, Rivero-Ayerza M, Gorenek B, Rodriguez C, Hopman WM, Baranchuk A (2013) Fragmented QRS as a predictor of arrhythmic events in patients with hypertrophic obstructive cardiomyopathy. J Interv Card Electrophysiol 38:159–165. https://doi.org/10.1007/s10840-013-9829-z
doi: 10.1007/s10840-013-9829-z
pubmed: 24013705
Kang KW, Janardhan AH, Jung KT, Lee HS, Lee MH, Hwang HJ (2014) Fragmented QRS as a candidate marker for high-risk assessment in hypertrophic cardiomyopathy. Heart Rhythm 11:1433–1440. https://doi.org/10.1016/j.hrthm.2014.05.002
doi: 10.1016/j.hrthm.2014.05.002
pubmed: 24813377
Lu X, Wang W, Zhu L, Wang Y, Sun K, Zou Y, Tian T, Hui R, Wang J, Kang L, Song L (2017) Prognostic significance of fragmented QRS in patients with hypertrophic cardiomyopathy. Cardiology 138:26–33. https://doi.org/10.1159/000471845
doi: 10.1159/000471845
pubmed: 28554182
Nomura A, Konno T, Fujita T, Tanaka Y, Nagata Y, Tsuda T, Hodatsu A, Sakata K, Nakamura H, Kawashiri MA, Fujino N, Yamagishi M, Hayashi K (2015) Fragmented QRS predicts heart failure progression in patients with hypertrophic cardiomyopathy. Circ J 79:136–143. https://doi.org/10.1253/circj.CJ-14-0822
doi: 10.1253/circj.CJ-14-0822
pubmed: 25381793
Rattanawong P, Riangwiwat T, Kanitsoraphan C, Chongsathidkiet P, Kanjanahattakij N, Vutthikraivit W, Chung EH (2018) Baseline fragmented QRS increases the risk of major arrhythmic events in hypertrophic cardiomyopathy: systematic review and meta-analysis. Ann Noninvasive Electrocardiol 23:e12533. https://doi.org/10.1111/anec.12533
doi: 10.1111/anec.12533
pubmed: 29363882
pmcid: 6931605
Haukilahti MA, Eranti A, Kenttä T, Huikuri HV (2016) QRS fragmentation patterns representing myocardial scar need to be separated from benign normal variants: hypotheses and proposal for morphology based classification. Front Physiol 7:653. https://doi.org/10.3389/fphys.2016.00653
doi: 10.3389/fphys.2016.00653
pubmed: 28082919
pmcid: 5183580
Wilson MG, Sharma S, Carré F, Charron P, Richard P, O’Hanlon R, Prasad SK, Heidbuchel H, Brugada J, Salah O, Sheppard M, George KP, Whyte G, Hamilton B, Chalabi H (2012) Significance of deep T-wave inversions in asymptomatic athletes with normal cardiovascular examinations: practical solutions for managing the diagnostic conundrum. Br J Sports Med 46(Suppl 1):i51-58. https://doi.org/10.1136/bjsports-2011-090838
doi: 10.1136/bjsports-2011-090838
pubmed: 23097480
Konno T, Fujino N, Hayashi K, Uchiyama K, Masuta E, Katoh H, Sakamoto Y, Tsubokawa T, Ino H, Yamagishi M (2007) Differences in the diagnostic value of various criteria of negative T waves for hypertrophic cardiomyopathy based on a molecular genetic diagnosis. Clin Sci (Lond) 112:577–582. https://doi.org/10.1042/cs20060293
doi: 10.1042/cs20060293
Lakdawala NK, Thune JJ, Maron BJ, Cirino AL, Havndrup O, Bundgaard H, Christiansen M, Carlsen CM, Dorval JF, Kwong RY, Colan SD, Køber LV, Ho CY (2011) Electrocardiographic features of sarcomere mutation carriers with and without clinically overt hypertrophic cardiomyopathy. Am J Cardiol 108:1606–1613. https://doi.org/10.1016/j.amjcard.2011.07.019
doi: 10.1016/j.amjcard.2011.07.019
pubmed: 21943931
pmcid: 3215918
Sharma S, Drezner JA, Baggish A, Papadakis M, Wilson MG, Prutkin JM, La Gerche A, Ackerman MJ, Borjesson M, Salerno JC, Asif IM, Owens DS, Chung EH, Emery MS, Froelicher VF, Heidbuchel H, Adamuz C, Asplund CA, Cohen G, Harmon KG, Marek JC, Molossi S, Niebauer J, Pelto HF, Perez MV, Riding NR, Saarel T, Schmied CM, Shipon DM, Stein R, Vetter VL, Pelliccia A, Corrado D (2018) International recommendations for electrocardiographic interpretation in athletes. Eur Heart J 39:1466–1480. https://doi.org/10.1093/eurheartj/ehw631
doi: 10.1093/eurheartj/ehw631
pubmed: 28329355
Calore C, Zorzi A, Sheikh N, Nese A, Facci M, Malhotra A, Zaidi A, Schiavon M, Pelliccia A, Sharma S, Corrado D (2016) Electrocardiographic anterior T-wave inversion in athletes of different ethnicities: differential diagnosis between athlete’s heart and cardiomyopathy. Eur Heart J 37:2515–2527. https://doi.org/10.1093/eurheartj/ehv591
doi: 10.1093/eurheartj/ehv591
pubmed: 26578198
Flett AS, Maestrini V, Milliken D, Fontana M, Treibel TA, Harb R, Sado DM, Quarta G, Herrey A, Sneddon J, Elliott P, McKenna W, Moon JC (2015) Diagnosis of apical hypertrophic cardiomyopathy: T-wave inversion and relative but not absolute apical left ventricular hypertrophy. Int J Cardiol 183:143–148. https://doi.org/10.1016/j.ijcard.2015.01.054
doi: 10.1016/j.ijcard.2015.01.054
pubmed: 25666123
pmcid: 4392393
Pennacchini E, Musumeci MB, Conte MR, Stöllberger C, Formisano F, Bongioanni S, Francia P, Volpe M, Autore C (2015) Electrocardiographic evolution in patients with hypertrophic cardiomyopathy who develop a left ventricular apical aneurysm. J Electrocardiol 48:818–825. https://doi.org/10.1016/j.jelectrocard.2015.06.004
doi: 10.1016/j.jelectrocard.2015.06.004
pubmed: 26116312
Suwa K, Satoh H, Sano M, Nobuhara M, Saitoh T, Saotome M, Urushida T, Katoh H, Tawarahara K, Ohtani H, Wakabayashi Y, Takase H, Terada H, Takehara Y, Sakahara H, Hayashi H (2014) Functional, morphological and electrocardiographical abnormalities in patients with apical hypertrophic cardiomyopathy and apical aneurysm: correlation with cardiac MR. Open Heart 1:e000124. https://doi.org/10.1136/openhrt-2014-000124
doi: 10.1136/openhrt-2014-000124
pubmed: 25332823
pmcid: 4189224
Tangwiwat C, Kaolawanich Y, Krittayaphong R (2019) Electrocardiographic predictors of myocardial fibrosis and apical hypertrophic cardiomyopathy. Ann Noninvasive Electrocardiol 24:e12612. https://doi.org/10.1111/anec.12612
doi: 10.1111/anec.12612
pubmed: 30403441
Lambiase PD, Gold MR, Hood M, Boersma L, Theuns D, Burke MC, Weiss R, Russo AM, Kääb S, Knight BP (2016) Evaluation of subcutaneous ICD early performance in hypertrophic cardiomyopathy from the pooled EFFORTLESS and IDE cohorts. Heart Rhythm 13:1066–1074. https://doi.org/10.1016/j.hrthm.2016.01.001
doi: 10.1016/j.hrthm.2016.01.001
pubmed: 26767422
Elliott PM, Kaski JC, Prasad K, Seo H, Slade AK, Goldman JH, McKenna WJ (1996) Chest pain during daily life in patients with hypertrophic cardiomyopathy: an ambulatory electrocardiographic study. Eur Heart J 17:1056–1064. https://doi.org/10.1093/oxfordjournals.eurheartj.a015002
doi: 10.1093/oxfordjournals.eurheartj.a015002
pubmed: 8809524
Elliott PM, Rosano GM, Gill JS, Poole-Wilson PA, Kaski JC, McKenna WJ (1996) Changes in coronary sinus pH during dipyridamole stress in patients with hypertrophic cardiomyopathy. Heart 75:179–183. https://doi.org/10.1136/hrt.75.2.179
doi: 10.1136/hrt.75.2.179
pubmed: 8673758
pmcid: 484256
Lazzeroni E, Picano E, Morozzi L, Maurizio AR, Palma G, Ceriati R, Iori E, Barilli A (1997) Dipyridamole-induced ischemia as a prognostic marker of future adverse cardiac events in adult patients with hypertrophic cardiomyopathy. Echo Persantine Italian Cooperative (EPIC) Study Group. Subproject Hypertrophic Cardiomyopathy Circulation 96:4268–4272. https://doi.org/10.1161/01.cir.96.12.4268
doi: 10.1161/01.cir.96.12.4268
pubmed: 9416892
Ogata Y, Hiyamuta K, Terasawa M, Ohkita Y, Bekki H, Koga Y, Toshima H (1986) Relationship of exercise or pacing induced ST segment depression and myocardial lactate metabolism in patients with hypertrophic cardiomyopathy. Jpn Heart J 27:145–158. https://doi.org/10.1536/ihj.27.145
doi: 10.1536/ihj.27.145
pubmed: 3723792
Aquino NJ, Centurión OA, Torales JM, Miño LM, Scavenius KE, Alderete JF, Candia JC, García LB, Cáceres C, Martínez JE, Lovera OA (2019) Association of QRS complex fragmentation with QT interval prolongation in patients with ischemic heart disease. Curr Health Sci J 45:398–404. https://doi.org/10.12865/chsj.45.04.08
doi: 10.12865/chsj.45.04.08
pubmed: 32110442
pmcid: 7014980
Jouven X, Hagege A, Charron P, Carrier L, Dubourg O, Langlard JM, Aliaga S, Bouhour JB, Schwartz K, Desnos M, Komajda M (2002) Relation between QT duration and maximal wall thickness in familial hypertrophic cardiomyopathy. Heart 88:153–157. https://doi.org/10.1136/heart.88.2.153
doi: 10.1136/heart.88.2.153
pubmed: 12117842
pmcid: 1767224
Johnson JN, Grifoni C, Bos JM, Saber-Ayad M, Ommen SR, Nistri S, Cecchi F, Olivotto I, Ackerman MJ (2011) Prevalence and clinical correlates of QT prolongation in patients with hypertrophic cardiomyopathy. Eur Heart J 32:1114–1120. https://doi.org/10.1093/eurheartj/ehr021
doi: 10.1093/eurheartj/ehr021
pubmed: 21345853
pmcid: 3086898